Remove DNA Remove In-Vivo Remove RNA Remove Vaccination
article thumbnail

Leading innovators in mammalian expression vectors for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These systems include human and mouse cell lines, and even in vivo in live animals.

In-Vivo 130
article thumbnail

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

The Pharma Data

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Using gene therapy to live longer, healthier lives

Drug Discovery World

Life Biosciences’ gene therapy approach differs from traditional gene replacement and gene editing approaches in that the company are not altering the DNA sequence. The company has shown that ER-100 can improve vision and visual function in mouse models of ageing, optic nerve crush, and glaucoma.

article thumbnail

Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease

WCG Clinical

T cells and B cells — both specialized white blood cells called “lymphocytes”– represent the two arms of the adaptive immune system responsible for immune memory and recall responses to vaccines and infections. The currently approved CD-19 CAR products are autologous, ex vivo cellular therapies.

In-Vivo 52
article thumbnail

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

Xtalks spoke to lead author on the study, Mohamed Abdel-Mohsen, PhD, assistant professor, Vaccine & Immunotherapy Center at the Wistar Institute, about the emerging utility of identifying glycomic, or sugar, signatures on the surface of immune cells to help in their identification and potential targeting.

RNA 52
article thumbnail

The Booming Potential of mRNA Technology

Roots Analysis

Vaccinations in the past have always been either weak or inactive forms of a pathogen which was given to the body so that our immune system is trained to recognize that given pathogen. There are several advantages to approaching vaccination this way. Ribosomes are cellular machines that read mRNA sequences and produce proteins.

Protein 40
article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7